Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NQO2 | P16083 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 3/20 | 0.44 |
| ▸ | MAPT | P10636 | 3/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | CASP6 | P55212 | 1/20 | 0.44 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.44 |
| ▸ | RELA | Q04206 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | TXNRD1 | Q16881 | 2/20 | 0.40 |
| ▸ | TXNRD3 | Q86VQ6 | 2/20 | 0.40 |
| ▸ | TXNRD2 | Q9NNW7 | 2/20 | 0.40 |
| ▸ | GLA | P06280 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 4/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28553829 | 0.75 | NQO2 (0.51) | NQO2ALDH1A1CYP3A4HTTMAPT | |
| SCHEMBL15007822 | 0.75 | MAPT (0.68) | NQO2ALDH1A1HTTMAPTKDM4E | |
| SCHEMBL6782564 | 0.72 | NQO2 (0.45) | NQO2ALDH1A1CYP3A4HTTMAPT | |
| SCHEMBL23363761 | 0.72 | NQO2 (0.45) | NQO2ALDH1A1CYP3A4HTTMAPT | |
| SCHEMBL24373627 | 0.71 | ESR2 (0.39) | NQO2ALDH1A1HTTKDM4ESMN1; SMN2 | |
| SCHEMBL27487952 | 0.70 | NQO2 (0.50) | NQO2ALDH1A1CYP3A4HTTMAPT | |
| SCHEMBL19762910 | 0.70 | NQO2 (0.47) | NQO2ALDH1A1CYP3A4HTTMAPT | |
| SCHEMBL994720 | 0.70 | MEN1 (0.56) | NQO2ALDH1A1CYP3A4HTTMAPT | |
| SCHEMBL17875688 | 0.70 | NQO2 (0.45) | NQO2ALDH1A1CYP3A4HTTMAPT | |
| SCHEMBL212004 | 0.69 | TXNRD1 (0.58) | ALDH1A1CYP3A4MAPTSMN1; SMN2TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250171464-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE | GENENTECH, INC. (US) | 2025-05-29 | — | — | US | disclosed |
| WO-2025084787-A1 | NOVEL QUINOXALINE COMPOUNDS, MANUFACTURING METHOD THEREOF, AND USES THEREOF | 가천대학교 산학협력단 | 2025-04-24 | — | — | WO | disclosed |
| US-12275745-B2 | Therapeutic compounds and methods of use | GENENTECH, INC. (US) | 2025-04-15 | — | — | US | disclosed |
| EP-4490159-A1 | TRICYCLIC HETEROCYCLE COMPOUNDS AS IAP ANTAGONISTS | Ascentage Pharma (Suzhou) Co., Ltd. (CN) | 2025-01-15 | — | — | EP | disclosed |
| EP-4436969-A2 | BICYCLIC THERAPEUTIC COMPOUNDS AND METHODS OF USE IN THE TREATMENT OF CANCER | Genentech, Inc. (US) | 2024-10-02 | — | — | EP | disclosed |
| CN-118451077-A | Bicyclic therapeutic compounds and methods for treatment of cancer | 基因泰克公司 | 2024-08-06 | — | — | CN | disclosed |
| WO-2023169569-A1 | TRICYCLIC HETEROCYCLE COMPOUNDS AS IAP ANTAGONISTS | ASCENTAGE PHARMA (SUZHOU) CO., LTD. (CN) | 2023-09-14 | — | — | WO | disclosed |
| CN-116731016-A | Tricyclic heterocyclic compounds as IAP antagonists | 苏州亚盛药业有限公司 | 2023-09-12 | — | — | CN | disclosed |
| US-20230219986-A1 | NOVEL AMINOPYRIMIDINE EGFR INHIBITOR | QILU PHARMACEUTICAL CO., LTD. (CN) | 2023-07-13 | — | — | US | disclosed |
| US-20230203062-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE | GENENTECH, INC. (US) | 2023-06-29 | — | — | US | disclosed |
| US-20230203062-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE | GENENTECH, INC. (US) | 2023-06-29 | — | — | US | disclosed |
| US-20230203062-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE | GENENTECH, INC. (US) | 2023-06-29 | — | — | US | disclosed |
| WO-2023097194-A2 | THERAPEUTIC COMPOUNDS AND METHODS OF USE | GENENTECH, INC. (US) | 2023-06-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250171464-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE | VHL, TP53, MCL1 | NQO2 115/4885ALDH1A1 829/4885CYP3A4 2755/4885 |
| US-20230203062-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE | VHL, TP53, MCL1 | NQO2 115/4885ALDH1A1 829/4885CYP3A4 2755/4885 |
| US-20230219986-A1 | NOVEL AMINOPYRIMIDINE EGFR INHIBITOR | EGFR, ERBB2, ERBB4 | NQO2 3101/4885ALDH1A1 2690/4885CYP3A4 3314/4885 |
| US-12275745-B2 | Therapeutic compounds and methods of use | VHL, TP53, MCL1 | NQO2 115/4885ALDH1A1 829/4885CYP3A4 2755/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.